Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Wilsons Drug & Device Conference 2023
13 slides from Pyc Therapeutics's conference presentation, Oct 26, 2023
Slide 1: Wilsons Drug & Device Conference Presentation
26 October 2023 WILSONS DRUG & DEVICE CONFERENCE PRESENTATION PERTH, Australia and SAN FRANCISCO, California – 26 October 2023 PYC Therapeutics Limited (ASX:PYC) is pleased to provide a copy of the presentation that will be given by PYC’s CEO, Dr Rohan Hockings, at the Wilsons Drug & Device Conferen
Slide 2: For personal use only
This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. This ASX announcement was approved and authorised for
Slide 3: Life-changing science
For personal use only Life-changing science Wilsons Healthcare Conference October 2023
Slide 4: Disclaimer
Disclaimer For personal use only The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. A
Slide 5: Executive Summary
Executive Summary • RNA therapeutics are one of the fastest growing modalities within the pharmaceutical industry For personal use only • Delivery remains the single greatest obstacle to realising the full potential of this class of drug • PYC’s drug delivery technology overcomes this challenge - en
Slide 6: RNA therapies are set for "extreme acceleration"
For personal use only RNA therapies are set for ”extreme acceleration“ Sanofi¹ PYC THERAPEUTICS 4 1. The Australian. “‘Punching above our weight’ in RNA field, says Ed Husic”. 9 October 2023
Slide 7: But they have an Achilles heel – delivering sufficient drug inside the target cell
But they have an Achilles heel – delivering sufficient drug inside the target cell For personal use only “While everybody else was so hyped and giving Nobel Prizes for CRISPR and all that, we realized those weren’t really the limitations The limitations were really delivery” George Yancopoulos, Pres
Slide 8: PYC's non-viral drug delivery platform extends the reach of RNA therapies
PYC’s non-viral drug delivery platform extends the reach of RNA therapies to new disease indications PYC achieves ~100x the target engagement of the ‘naked’ RNA drug in vivo¹ For personal use only PYC combines existing RNA drug design technology PYC’s delivery platform is used to assist the with its
Slide 9: PYC's drug delivery technology opens up new possibilities in areas of major unmet patient need
PYC’s drug delivery technology opens up new possibilities in areas of major unmet patient need Vehicle OPA1 protein (stained in red) A single safe and well- For personal use only Cell nuclei (stained in blue) Untreated control establishes baseline expression of OPA1 protein in the tolerated dose of
Slide 10: PYC's drug candidates have demonstrated efficacy in 3D models derived from patients
PYC’s drug candidates have already demonstrated efficacy in 3D models derived from patients with the target disease For personal use only PYC THERAPEUTICS 8 1. Refer ASX announcement 20 October 2023
Slide 11: Drugs targeting single gene mutations are much more likely to succeed
Drugs targeting diseases caused by single gene mutations are much more likely to succeed in clinical development For personal use only PYC THERAPEUTICS 9 1. https://news.alnylam.com/rnai/articles/harnessing-human-genetics-power-next-wave-rnai-therapeutics
Slide 12: PYC has multiple first-in-class assets addressing the root cause of unmet need
PYC has multiple first-in-class assets that address the root cause of a major unmet patient need For personal use only “It’s hard for me to think of a higher level of target validation, at least for an unapproved drug, than human genetic validation” “What matters is having really high-quality projec
Slide 13: These assets will provide human data read-outs within the next 36 months
These assets will provide 5 human data read-outs within the next 36 months¹ WITHIN 12 MONTHS WITHIN 24 MONTHS WITHIN 36 MONTHS For personal use only Formal safety read-out Efficacy read-outs Pivotal/Registrational Retinitis Pigmentosa Type 11 (Phase 1) + Efficacy insights (Phase 2) trial (Phase 3) I
PYC Therapeutics — Wilsons Drug & Device Conference 2023 on 6ix